Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) is a dermatology therapeutics company whose news flow centers on clinical milestones, regulatory developments, commercial progress and financing activities related to its skin disease portfolio. The company’s updates frequently highlight YCANTH® (VP-102), a cantharidin-based, healthcare professional-administered treatment approved by the FDA for molluscum contagiosum, and its expansion into new indications and geographies.
Investors following VRCA news can expect regular announcements on YCANTH’s commercial performance in the United States, including dispensed applicator trends and net product revenue, as well as collaboration and milestone revenue from Torii Pharmaceutical Co. Ltd. in Japan. News items also cover regulatory interactions, such as positive feedback from the European Medicines Agency’s Committee for Medicinal Products for Human Use supporting a Marketing Authorization Application for YCANTH in the European Union, and approval of TO-208 (YCANTH) for molluscum contagiosum in Japan.
Another major theme in Verrica’s news is pipeline progress. The company reports data from clinical trials of YCANTH in common warts, including Phase 2 results and the initiation of a global Phase 3 program, and provides detailed updates on VP-315, its oncolytic peptide immunotherapy for non-melanoma skin cancers such as basal cell carcinoma. Presentations at scientific meetings, exploratory immunologic analyses and alignment with the U.S. Food and Drug Administration on Phase 3 study designs are common subjects of these releases.
VRCA news also includes corporate and capital markets developments, such as private placement financings, reverse stock split actions, Nasdaq listing compliance updates and conference presentations at investor events. For readers interested in dermatology therapeutics, viral skin infections and non-melanoma skin cancer programs, the Verrica news page offers a consolidated view of the company’s clinical, regulatory, commercial and financial disclosures over time.
Verrica Pharmaceuticals (NASDAQ: VRCA) presented three posters featuring clinical data from Part 2 of their Phase 2 study of VP-315, a novel oncolytic peptide for treating basal cell carcinoma (BCC), at the 2025 Winter Clinical Dermatology Conference. The study, involving 82 patients with 91 tumors, demonstrated a 97% Calculated Objective Response Rate.
Key findings include: 51% of tumors achieved complete histological clearance, while remaining patients showed an average 71% reduction in tumor size. The treatment showed favorable safety profiles with no Treatment Related Serious Adverse Events, and mostly mild to moderate adverse events.
The company plans to request an End-of-Phase 2 meeting with the FDA in first half of 2025, with genomic and T-cell data expected in Q1 2025. Verrica believes VP-315 could serve as a first-line therapy in both primary and neoadjuvant settings, potentially representing a multi-billion-dollar opportunity as a non-surgical alternative for BCC patients.
Verrica Pharmaceuticals (NASDAQ: VRCA) reports positive momentum in Q4 2024, with YCANTH dispensed applicator units surpassing the previous quarter's numbers despite cost reductions. The company notes significant reduction in distributor inventory levels and plans to launch a single applicator configuration in Q1 2025 to enhance accessibility and reduce costs for physician practices.
The company is expanding distribution through local independent pharmacies while implementing targeted cost management. The new single applicator packaging aims to facilitate initial purchases and increase patient access through buying groups, hospitals, and government entities. Verrica continues to advance its pipeline, including YCANTH for common warts in partnership with Torii Pharmaceutical, and VP-315, an oncolytic peptide showing promising Phase 2 results for basal cell carcinoma treatment.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, has announced the granting of a nonqualified stock option to its new Chief Operating Officer, David Zawitz. The grant includes options to purchase 950,000 shares of common stock under the Company's Inducement Plan, effective December 9, 2024.
The stock option, granted as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4), will have an exercise price equal to the closing price of Verrica's common stock on December 9, 2024. The vesting schedule includes 1/8th of shares after six months and 1/48th monthly thereafter, subject to continuous service.
Verrica Pharmaceuticals announced that its partner Torii Pharmaceutical has submitted a New Drug Application (NDA) for TO-208 to treat Molluscum Contagiosum in Japan. TO-208, marketed as YCANTH® in the U.S., demonstrated superiority to vehicle in Phase 3 clinical studies with Japanese patients aged ≥2 years, showing a safety profile consistent with U.S. studies.
The development addresses an estimated 1.6 million cases of molluscum in Japan, representing a significant unmet medical need. This submission follows Torii's exclusive license agreement with Verrica in March 2021 for development and commercialization in Japan. Notably, VP-102 received U.S. approval in July 2023 and has been marketed as YCANTH® since August 2023.
Verrica Pharmaceuticals (Nasdaq: VRCA) has announced the pricing of a $42.0 million public offering. The offering includes 44,964,045 shares of common stock and pre-funded warrants to purchase 2,235,955 shares. Additionally, the offering includes Series A warrants to purchase 23,600,000 shares at $1.0680 per share and Series B warrants for 23,600,000 shares at $1.3350 per share. The combined offering price is $0.89 per share with accompanying warrants. Jefferies is serving as the sole book-running manager, and the offering is expected to close on November 22, 2024.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, announced a proposed underwritten public offering of common stock and accompanying warrants. The offering includes an option for the underwriter to purchase up to 15% additional shares and/or warrants within 30 days. Jefferies is acting as the sole book-running manager. The offering will be conducted under a shelf registration statement filed with the SEC. The final size and terms are subject to market conditions.
Verrica Pharmaceuticals reported negative net product revenue of $1.9M in Q3 2024, including a $1.7M provision for product returns. The company announced significant operational changes, including new leadership appointments of Dr. Jayson Rieger as CEO and John Kirby as Interim CFO. A restructuring effort reduced operating expenses by approximately 50% through territory optimization and headcount reduction. YCANTH dispensed applicator units increased to 7,706 in Q3 2024 from 5,975 in Q2. The company expects existing distributor inventory to support demand into Q1 2025. Cash position stands at $23M, projected to support operations into Q1 2025.
Verrica Pharmaceuticals (NASDAQ: VRCA) announced positive preliminary results from Part 2 of their Phase 2 study for VP-315, a novel oncolytic peptide treatment for basal cell carcinoma (BCC). The study, involving 82 patients with 92 tumors, showed that 51% of treated tumors achieved complete histological clearance, while patients with residual tumors experienced an average 71% reduction in tumor size. The treatment demonstrated a favorable safety profile with no serious adverse events. Two abstracts featuring these results will be presented at the 2024 Fall Clinical Dermatology Conference. The company plans to request an FDA End-of-Phase 2 meeting in first half 2025, targeting the 3-4 million annual BCC cases in the U.S.
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced a significant restructuring of its commercial organization to reduce costs and expand access to YCANTH®, its treatment for molluscum contagiosum. The company plans to:
- Reduce sales territories from 80 to approximately 35
- Focus on territories with high molluscum prevalence, previous cantharidin users, and strong insurance coverage for YCANTH®
- Expand sales efforts to include pediatricians in addition to dermatologists
- Reduce headcount in certain support functions
These changes are expected to reduce the company's overall cost structure by approximately 50% while maintaining support for YCANTH® as the new standard of care for molluscum contagiosum. The restructuring will result in a one-time charge of approximately $1.0 million.
Verrica Pharmaceuticals (Nasdaq: VRCA), a dermatology therapeutics company, announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference in New York City. The event is scheduled for September 9-11, 2024. Ted White, President and CEO of Verrica, will engage in a fireside chat on Monday, September 9, 2024, at 1:30 pm ET.
Interested parties can access a live webcast of the event through a provided link or via the Investors/Presentations & Events section of Verrica's website. A replay of the webcast will be available for 90 days following the event, offering extended access to those unable to attend live.